Personal information

Websites & social links

Borgeson lab website
Wallenberg Fellow website
Emma Börgeson at Aarhus University
Emma Börgeson at Steno Diabetes Centre Aarhus

Other IDs

Loop profile: 52653

Countries

Sweden, Denmark

Activities

Collapse all

Employment (3)

Aarhus University: Aarhus, DK

2022-10-01 to present | Associate Professor (Department of Biomedicine)
Employment
Source: Self-asserted source
Emma Börgeson

Sahlgrenska University Hospital: Gothenburg, SE

2018-08-01 to present | Principle investigator ( Clinical Immunology and Transfusion Medicine )
Employment
Source: Self-asserted source
Emma Börgeson

University of Gothenburg: Gothenburg, SE

2016-03-01 to 2022-10-01 | Professor (Associate) (The Wallenberg Laboratory for Cardiovascular and Metabolic Research)
Employment
Source: Self-asserted source
Emma Börgeson

Education and qualifications (8)

Aarhus University: Aarhus, DK

2024-01 to 2024-06 | Continued Pedagogical Education (5 ECTS): Aarhus University Pedagogical Programme (Biomedicine)
Education
Source: Self-asserted source
Emma Börgeson

University of Gothenburg: Gothenburg, SE

2016 to 2021 | Continued Pedagogical Education (20 ECTS): Supervision in Postgraduate Programmes; Teaching and Learning in Higher Education; Higher Education Teaching in Natural Sciences; Applied Analysis;
Education
Source: Self-asserted source
Emma Börgeson

University of California San Diego: La Jolla, CA, US

2012-07-01 to 2016-06-01 | Post-doctoral Marie Curie Research Fellow (School of Medicine)
Education
Source: Self-asserted source
Emma Börgeson

University College Dublin: Dublin, IE

2012-06-01 to 2015-06-01 | Post-doctoral Marie Curie Research Fellow (School of Medicine and Medical Sciences)
Education
Source: Self-asserted source
Emma Börgeson

University College Dublin: Dublin, IE

2007-09-01 to 2011-12-06 | PhD in Medicine (School of Medicine and Medical Sciences )
Education
Source: Self-asserted source
Emma Börgeson

Linköpings universitet: Linkoping, SE

2006-08-01 to 2007-06-01 | Masters Degree: Biomedical Research School
Education
Source: Self-asserted source
Emma Börgeson

Linköpings universitet: Linkoping, SE

2006-08-01 to 2007-06-01 | Master’s degree in Medical Biology
Education
Source: Self-asserted source
Emma Börgeson

Linköpings universitet: Linkoping, SE

2003-08-01 to 2006-06-01 | Bachelor’s degree in Science
Education
Source: Self-asserted source
Emma Börgeson

Professional activities (9)

Aarhus University: Aarhus, DK

2023 to present | Steering Committee Member of The Food and Nutrition Network, Aarhus University (Biomedicine)
Membership
Source: Self-asserted source
Emma Börgeson

Aarhus Universitet: Aarhus, DK

2023 to present | Co-chair of the Cardiovascular Network, Aarhus University (Biomedicine)
Membership
Source: Self-asserted source
Emma Börgeson

Norway Regional Health Authority: Oslo, NO

2022 to present | Study Section Member
Invited position
Source: Self-asserted source
Emma Börgeson

SNSF: Bern, CH

2020 to present | Head of Study Section, Biology & Medicine
Invited position
Source: Self-asserted source
Emma Börgeson

Swedish Research Council: Stockholm, SE

2024 to 2024 | Study Section Member
Invited position
Source: Self-asserted source
Emma Börgeson

VINNOVA: Stockholm, SE

2021 to 2024 | Study Section Member, Innovative environments in precision health
Invited position
Source: Self-asserted source
Emma Börgeson

EMBO: Heidelberg, DE

2022 | EMBO travel award, Spain
Distinction
Source: Self-asserted source
Emma Börgeson

Dutch Research Council: The Hague, NL

2021 to 2021 | External grant review expert
Invited position
Source: Self-asserted source
Emma Börgeson

European Research Council: Brussels, BE

2017 to 2017 | External grant review expert
Invited position
Source: Self-asserted source
Emma Börgeson

Funding (15)

En precisionsmedicinsk metod för användning av lipoxiner som läkemedel för att minska inflammation och obesitas-relaterade sjukdomar

2024 to 2028 | Grant
Swedish Research Council (Stockholm, SE)
Source: Self-asserted source
Emma Börgeson

Identifying lipoxin-responsive patients to reduce cardiometabolic disease

2024 to 2027 | Grant
Independent Research Fund Denmark (Odense, DK)
GRANT_NUMBER:

3165-00026B
Source: Self-asserted source
Emma Börgeson

Startup Funding

2022-10 to 2026-09 | Grant
NovoNordisk Foundation Center for Basic Metabolic Research (Copenhagen, DK)
GRANT_NUMBER:

NNF22OC0079363
Source: Self-asserted source
Emma Börgeson

Startup Funding

2022-10 to 2025-12 | Grant
Aarhus Universitets Forskningsfond (Aarhus, DK) (Aarhus, DK)
GRANT_NUMBER:

AUFF-E-2022-7-8
Source: Self-asserted source
Emma Börgeson

The Matrix

2019-09 to 2026-08 | Grant
European Commission (Brussels, BE)
GRANT_NUMBER:

804418

Source: Self-asserted source
Emma Börgeson

Inflammatorisk Resolution: nyckeln till metabol hälsa.

2016-03 to 2020-02 | Grant
Swedish Society for Medical Research (Stockholm, SE)
GRANT_NUMBER:

S150086
Source: Self-asserted source
Emma Börgeson

Lipoxiner: ett nytt sätt att främja metabol hälsa

2016-03 to 2020-02 | Grant
Vetenskapsrådet (Stockholm, SE)
GRANT_NUMBER:

2016/82
Source: Self-asserted source
Emma Börgeson

Inflammatory resolution in cardiometabolic health and disease

2016 to 2017 | Grant
National Institutes of Health (MD, MD, US)
GRANT_NUMBER:

DK097154
Source: Self-asserted source
Emma Börgeson

Inflammatory resolution: a novel therapeutic approach to treat metabolic disease

2016 to 2017 | Grant
Åke Wiberg’s Foundation (Gothenburg, SE)
GRANT_NUMBER:

M15-0058
Source: Self-asserted source
Emma Börgeson

Promoting metabolic health via anti-inflammatory lipids

2016 to 2017 | Grant
Konrad och Helfrid Johanssons Stiftelse (Gothenburg, SE)
GRANT_NUMBER:

Borgeson2016
Source: Self-asserted source
Emma Börgeson

The potential therapeutic role of lipoxins in diabetes and its associated complications

2007-08 to 2011-06 | Grant
Irish Research Council for Science, Engineering and Technology (Dublin, IE)
GRANT_NUMBER:

RS/2007/167
Source: Self-asserted source
Emma Börgeson

Investigating Porphyromonas gingivalis induced platelet activation

2007-06 to 2007-08 | Grant
Filip Lundbergs Foundation (Gothenburg, SE)
Source: Self-asserted source
Emma Börgeson

Therapeutic potential of Lipoxin A4 in attenuating bacterial-induced cardiovascular events

2007-06 to 2007-08 | Grant
Emil & Maria Palms Foundation (Gothenburg, SE)
Source: Self-asserted source
Emma Börgeson

Evaluating efferocytosis and inflammation in diabetic nephropathy.

2007-01 to 2007-06 | Grant
Anna Whitlock Memorial Foundation (Gothenburg, SE)
Source: Self-asserted source
Emma Börgeson

Synthesizing and evaluating the therapeutic potential of novel Benzo-LXA4 analogues

2007-01 to 2007-06 | Grant
Dr. Felix Neuberghs Foundation (Gothenburg, SE)
Source: Self-asserted source
Emma Börgeson

Works (24)

Inflammation and resolution in obesity

Nature Reviews Endocrinology
2025-01 | Journal article
DOI: 10.1038/s41574-024-01047-y
Contributors: Matúš Soták; Madison Clark; Bianca E. Suur; Emma Börgeson
Source: check_circle
Crossref

SERPINA3C as a mediator of metabolic health in offspring

Nature Metabolism
2025-01-31 | Journal article
DOI: 10.1038/s42255-024-01209-2
Contributors: Bianca E. Suur; Emma Börgeson
Source: check_circle
Crossref

The challenges of assessing adiposity in a clinical setting

Nature Reviews Endocrinology
2024-10 | Journal article
DOI: 10.1038/s41574-024-01012-9
Contributors: Emma Börgeson; Saeideh Tavajoh; Stephan Lange; Niels Jessen
Source: check_circle
Crossref

Attenuation of adipose tissue inflammation by pro-resolving lipid mediators

Current Opinion in Endocrine and Metabolic Research
2024-09 | Journal article
DOI: 10.1016/j.coemr.2024.100539
Contributors: Madison Clark; Bianca E. Suur; Matúš Soták; Emma Börgeson
Source: check_circle
Crossref

Healthy Subcutaneous and Omental Adipose Tissue Is Associated with High Expression of Extracellular Matrix Components

International Journal of Molecular Sciences
2022-01-04 | Journal article
DOI: 10.3390/ijms23010520
Contributors: Matúš Soták; Meenu Rohini Rajan; Madison Clark; Christina Biörserud; Ville Wallenius; Carolina E. Hagberg; Emma Börgeson
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The N2A region of titin has a unique structural configuration

Journal of General Physiology
2021-07-05 | Journal article
DOI: 10.1085/jgp.202012766
Contributors: Chiara Stronczek; Stephan Lange; Belinda Bullard; Sebastian Wolniak; Emma Börgeson; Olga Mayans; Jennifer R. Fleming
Source: check_circle
Crossref

Specialized Pro-Resolving Mediators and the Lymphatic System.

International journal of molecular sciences
2021-03-09 | Journal article
DOI: 10.3390/ijms22052750
PMID: 33803130
PMC: PMC7963193
Source: Self-asserted source
Emma Börgeson

Exploring Obscurin and SPEG Kinase Biology.

Journal of clinical medicine
2021-03-02 | Journal article
DOI: 10.3390/jcm10050984
PMID: 33801198
PMC: PMC7957886
Source: Self-asserted source
Emma Börgeson

Molecular Characterisation of Titin N2A and Its Binding of CARP Reveals a Titin/Actin Cross-linking Mechanism.

Journal of molecular biology
2021-02-27 | Journal article
DOI: 10.1016/j.jmb.2021.166901
PMID: 33647290
Source: Self-asserted source
Emma Börgeson

Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity.

Life sciences
2020-12-29 | Journal article
DOI: 10.1016/j.lfs.2020.118974
PMID: 33385407
Source: Self-asserted source
Emma Börgeson

Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum.

Scientific reports
2019-10-28 | Journal article
DOI: 10.1038/s41598-019-51673-0
PMID: 31659186
PMC: PMC6817872
Source: Self-asserted source
Emma Börgeson

miR-486 is modulated by stretch and increases ventricular growth

JCI Insight
2019-09-12 | Journal article
DOI: 10.1172/jci.insight.125507
Part of ISSN: 2379-3708
Source: Self-asserted source
Emma Börgeson
grade
Preferred source (of 3)‎

Obesity-induced changes in lipid mediators persist after weight loss

International Journal of Obesity
2018-04 | Journal article
DOI: 10.1038/ijo.2017.266
Part of ISSN: 0307-0565
Part of ISSN: 1476-5497
Source: Self-asserted source
Emma Börgeson
grade
Preferred source (of 2)‎

AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin

Diabetologia
2017-04 | Journal article
DOI: 10.1007/s00125-017-4211-9
Part of ISSN: 0012-186X
Part of ISSN: 1432-0428
Source: Self-asserted source
Emma Börgeson
grade
Preferred source (of 2)‎

The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice

Diabetologia
2016-03 | Journal article
DOI: 10.1007/s00125-015-3815-1
Part of ISSN: 0012-186X
Part of ISSN: 1432-0428
Source: Self-asserted source
Emma Börgeson
grade
Preferred source (of 2)‎

Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.

2015-06 | Journal article
PMID:

26052006
Contributors: Börgeson E; Johnson AM; Lee YS; Till A; Syed GH; Ali-Shah ST; Guiry PJ; Dalli J; Colas RA; Serhan CN et al.
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses.

2013-08 | Journal article
DOI:

10.1016/j.bbamcr.2013.03.027

PMID:

23567938
Contributors: Corcoran JB; McCarthy S; Griffin B; Gaffney A; Bhreathnach U; Börgeson E; Hickey FB; Docherty NG; Higgins DF; Furlong F et al.
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Obesity, immunomodulation and chronic kidney disease.

2013-08 | Journal article
DOI:

10.1016/j.coph.2013.05.011

PMID:

23751262
Contributors: Börgeson E; Sharma K
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

2013-03 | Journal article
DOI:

10.1681/ASN.2012060550

PMID:

23520204

PMC:

PMC3609134
Contributors: Brennan EP; Nolan KA; Börgeson E; Gough OS; McEvoy CM; Docherty NG; Higgins DF; Murphy M; Sadlier DM; Ali-Shah ST et al.
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.

2012 | Journal article
DOI:

10.3389/fimmu.2012.00318

PMID:

23087692

PMC:

PMC3474937
Contributors: Börgeson E; Godson C
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Lipoxin A4 attenuates adipose inflammation.

2012-10 | Journal article
DOI:

10.1096/fj.12-208249

PMID:

22700871
Contributors: Börgeson E; McGillicuddy FC; Harford KA; Corrigan N; Higgins DF; Maderna P; Roche HM; Godson C
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis.

2011-09 | Journal article
DOI:

10.1096/fj.11-185017

PMID:

21628447
Contributors: Börgeson E; Docherty NG; Murphy M; Rodgers K; Ryan A; O'Sullivan TP; Guiry PJ; Goldschmeding R; Higgins DF; Godson C
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Lipoxin A₄ inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression.

2011-04 | Journal article
DOI:

10.1128/IAI.00777-10

PMID:

21263017

PMC:

PMC3067532
Contributors: Börgeson E; Lönn J; Bergström I; Brodin VP; Ramström S; Nayeri F; Särndahl E; Bengtsson T
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Molecular circuits of resolution in renal disease.

2010 | Journal article
DOI:

10.1100/tsw.2010.120

PMID:

20623097
Contributors: Börgeson E; Godson C
Source: Self-asserted source
Emma Börgeson via Europe PubMed Central

Peer review (4 reviews for 3 publications/grants)

Review activity for EBioMedicine. (2)
Review activity for Nature (1)
Review activity for Nature metabolism. (1)
How many people are using ORCID?